Please select a video from the list below.
RESPITE: Evidence to Support a Switch Approach?
Dr. Jim White discusses data from RESPITE, a novel prospective open-label study that evaluated sildenafil and tadalafil treated patients who switched therapy to riociguat. To earn up to 1.25 FREE credit hours for viewing this and other programs in this series, click the link below.